Aortic valve replacement with the Mitroflow pericardial bioprosthesis: Durability results up to 21 years Charles A. Yankah, MD, PhD, Miralem Pasic, MD,

Slides:

Advertisements

Similar presentations

Tubular heart valves: A new tissue prosthesis design—Preclinical evaluation of the 3F aortic bioprosthesis James L. Cox, MD, Niv Ad, MD, Keith Myers, BS,

Advertisements

W. R. Eric Jamieson, MD, Clifton T. P. Lewis, MD, Marc P

Max B. Mitchell, MD The Journal of Thoracic and Cardiovascular Surgery

Of mice and men and surgical transcatheter aortic valve insertion

Clinical event rates with the On-X bileaflet mechanical heart valve: A multicenter experience with follow-up to 12 years John B. Chambers, MD, FRCP,

The fate of small-size pericardial heart valve prostheses in an older patient population Ruggero De Paulis, MD, Salvatore D'Aleo, MD, Alessandro Bellisario,

Aortic valve replacement in low-flow, low-gradient aortic stenosis: Left ventricular ejection fraction matters Victor Dayan, MD, PhD, Philippe Pibarot,

Influence of the On-X mechanical prosthesis on intermediate-term major thromboembolism and hemorrhage: A prospective multicenter study Vincent Chan,

Very Long-Term Outcomes of the Carpentier-Edwards Perimount Aortic Valve in Patients Aged 60 or Younger Thierry Bourguignon, MD, Rym El Khoury, MD, Pascal.

Scott Goldman, MD, Anson Cheung, MD, Joseph E. Bavaria, MD, Michael R

Sergey Leontyev, MD, Michael A

Lars G. Svensson, MD, PhD, Lillian H. Batizy, MS, Eugene H

In which patients is transcatheter aortic valve replacement potentially better indicated than surgery for redo aortic valve disease? Long-term results.

Fate of aortic bioprostheses: An 18-year experience

Hancock II Bioprosthesis for Aortic Valve Replacement: The Gold Standard of Bioprosthetic Valves Durability? Tirone E. David, MD, Susan Armstrong, MS,

Harald C. Eichstaedt, MD, Jerry Easo, MD, Tobias Härle, MD, Otto E

Usefulness of microsimulation to translate valve performance into patient outcome: Patient prognosis after aortic valve replacement with the Carpentier–Edwards.

Long-term prognosis of ascending aortic aneurysm after aortic valve replacement for bicuspid versus tricuspid aortic valve stenosis Evaldas Girdauskas,

When is the Ross operation a good option to treat aortic valve disease? Tirone E. David, MD, Anna Woo, MD, Susan Armstrong, MSc, Manjula Maganti, MSc

Long-term follow-up after aortic valve replacement with Edwards Prima Plus stentless bioprostheses in patients younger than 60 years of age Torsten Christ,

Eight-year results after aortic valve replacement with the CryoLife-O’Brien Stentless Aortic Porcine Bioprosthesis Ivo Martinovic, MD, Ibrahim Farah,

The fate of small-size pericardial heart valve prostheses in an older patient population Ruggero De Paulis, MD, Salvatore D'Aleo, MD, Alessandro Bellisario,

Patient outcome after aortic valve replacement with a mechanical or biological prosthesis: Weighing lifetime anticoagulant-related event risk against.

Bicuspid aortic valve aortopathy: One size fits all?

Long-term results of aortic valve–sparing operations in patients with Marfan syndrome Tirone E. David, MD, Sue Armstrong, BSc, Manjula Maganti, BSc, Jack.

Risk-corrected impact of mechanical versus bioprosthetic valves on long-term mortality after aortic valve replacement Ole Lund, MD, PhD, Martin Bland,

The lord of the rings Antonio Miceli, MD, PhD

Outcome after surgery for prosthetic valve endocarditis and the impact of preoperative treatment Herko Grubitzsch, MD, PhD, Andreas Schaefer, Christoph.

The variability of the mitral valve anatomy and terminology

Does the degree of preoperative mitral regurgitation predict survival or the need for mitral valve repair or replacement in patients with anomalous origin.

Long-term evaluation of biological versus mechanical prosthesis use at reoperative aortic valve replacement Vincent Chan, MD, MPH, B-Khanh Lam, MD, MPH,

John A. Elefteriades, MD, PhD (hon), Bulat A. Ziganshin, MD, PhD

W. R. Eric Jamieson, MD, Clifton T. P. Lewis, MD, Marc P

Transcatheter aortic valve replacement in intermediate-risk patients

Innovation and science: The future of valve design

Structural deterioration of the Freestyle aortic valve: Mode of presentation and mechanisms Siamak Mohammadi, MD, Richard Baillot, MD, Pierre Voisine,

Michele Gallo, MD, Gino Gerosa, MD

Stentless biological valved conduit for aortic root replacement: Initial experience with the Shelhigh BioConduit model NR-2000C Abdullah Kaya, MD, Robin.

Twenty-year experience with the St Jude Medical mechanical valve prosthesis John S Ikonomidis, MD, PhD, John M Kratz, MD, Arthur J Crumbley, MD, Martha.

Are allografts the biologic valve of choice for aortic valve replacement in nonelderly patients? Comparison of explantation for structural valve deterioration.

Intermediate results of isolated mitral valve replacement with a Biocor porcine valve Giulio Rizzoli, MD, Tomaso Bottio, MD, PhD, Vladimiro Vida, MD,

Transcatheter aortic valve replacement and surgical aortic valve replacement: Both excellent therapies J. James Edelman, MBBS(Hons), PhD, Vinod H. Thourani,

Surgery for aortic and mitral valve disease in the United States: A trend of change in surgical practice between 1998 and 2005 Scott D. Barnett, PhD,

Tirone E. David, MD, Gheorghe Gavra, MD, Christopher M

Jeevanantham Rajeswaran, PhD, Eugene H. Blackstone, MD

Fenton H. McCarthy, MD, MS, Nimesh D. Desai, MD, PhD

Replicating the success of mitral valve repair in the aortic valve

Bradley G. Leshnower, MD, Robert A. Guyton, MD, Richard J

Thirty-year experience with a bileaflet mechanical valve prosthesis

Passing the torch The Journal of Thoracic and Cardiovascular Surgery

The Mitroflow aortic valve: A past, present, and future illuminated

Hans-Joachim Schäfers, MD

Concomitant replacement of the ascending aorta is free—for some

Long-term results of Freestyle stentless bioprosthesis in the aortic position: A single- center prospective cohort of 500 patients Nicolas Amabile, MD,

The Journal of Thoracic and Cardiovascular Surgery

Discussion The Journal of Thoracic and Cardiovascular Surgery

The future of cardiac surgery training: A survival guide

Permanent pacemaker insertion following transcatheter aortic valve replacement: Not infrequent, not benign, and becoming predictable Craig M. Jarrett,

Long-term results of the Medtronic Mosaic porcine bioprosthesis in the aortic position Amedeo Anselmi, MD, Erwan Flécher, MD, PhD, Vito Giovanni Ruggieri,

Maral Ouzounian, MD, PhD, Amine Mazine, MD, MSc, Tirone E. David, MD

Vinay Badhwar, MD, John S. Ikonomidis, MD, PhD, Jeffrey P. Jacobs, MD

“The more things change…”: The challenges ahead

Valve-sparing aortic root replacement in bicuspid aortic valves: A reasonable option? Diana Aicher, MD, Frank Langer, MD, Anke Kissinger, Henning Lausberg,

Chordal replacement with polytetrafluoroethylene sutures for mitral valve repair: A 25- year experience Tirone E. David, MD, Susan Armstrong, MSc, Joan.

Did you like Terminator 3 better than Terminator 2

Durability of pericardial versus porcine bioprosthetic heart valves

Which biologic valve should we select for the 45- to 65-year-old age group requiring aortic valve replacement? F. Dagenais, MD, P. Cartier, MD, P. Voisine,

Thanos Sioris, MD, Tirone E

Paul Philipp Heinisch, MD, Thierry Carrel, MD

Is early antithrombotic therapy necessary in patients with bioprosthetic aortic valves in normal sinus rhythm? Andrew W. ElBardissi, MD, MPH, Daniel.

Presentation transcript:

Aortic valve replacement with the Mitroflow pericardial bioprosthesis: Durability results up to 21 years Charles A. Yankah, MD, PhD, Miralem Pasic, MD, PhD, Michele Musci, MD, Julia Stein, MSc, Christine Detschades, SRN, Henryk Siniawski, MD, PhD, Roland Hetzer, MD, PhD The Journal of Thoracic and Cardiovascular Surgery Volume 136, Issue 3, Pages 688-696 (September 2008) DOI: 10.1016/j.jtcvs.2008.05.022 Copyright © 2008 The American Association for Thoracic Surgery Terms and Conditions

Figure 1 Overall cumulative survival of all 1513 patients after aortic valve replacement and of a German population as background (data from Federal Bureau for Population Statistics, Wiesbaden, Germany). The Journal of Thoracic and Cardiovascular Surgery 2008 136, 688-696DOI: (10.1016/j.jtcvs.2008.05.022) Copyright © 2008 The American Association for Thoracic Surgery Terms and Conditions

Figure 2 Actuarial freedom from reoperation for structural valve deterioration (SVD) in age groups (50–59, 60–69, and ≥70 years) after pericardial aortic valve replacement. The Journal of Thoracic and Cardiovascular Surgery 2008 136, 688-696DOI: (10.1016/j.jtcvs.2008.05.022) Copyright © 2008 The American Association for Thoracic Surgery Terms and Conditions

Figure 3 Actual (cumulative incidence) freedom from reoperation for structural valve deterioration (SVD) by age group (50–59, 60–69 and ≥70 years) after pericardial aortic valve replacement. The Journal of Thoracic and Cardiovascular Surgery 2008 136, 688-696DOI: (10.1016/j.jtcvs.2008.05.022) Copyright © 2008 The American Association for Thoracic Surgery Terms and Conditions

Figure 4 Actuarial and actual (cumulative incidence) freedom from reoperation for structural valve deterioration (SVD) in age group ≥65 years after pericardial aortic valve replacement. The Journal of Thoracic and Cardiovascular Surgery 2008 136, 688-696DOI: (10.1016/j.jtcvs.2008.05.022) Copyright © 2008 The American Association for Thoracic Surgery Terms and Conditions

Figure 5 Time-related transvalvular mean gradients in relation to labeled valve sizes. Each symbol represents a labeled valve size. Solid lines represent time-related estimates of median values for each prosthesis. The Journal of Thoracic and Cardiovascular Surgery 2008 136, 688-696DOI: (10.1016/j.jtcvs.2008.05.022) Copyright © 2008 The American Association for Thoracic Surgery Terms and Conditions

Figure 6 Actuarial freedom from thromboembolism (TE) after pericardial aortic valve replacement. The Journal of Thoracic and Cardiovascular Surgery 2008 136, 688-696DOI: (10.1016/j.jtcvs.2008.05.022) Copyright © 2008 The American Association for Thoracic Surgery Terms and Conditions

Figure 7 Hazard function of prosthetic valve endocarditis after pericardial aortic valve replacement. Constant hazard rate of events. The Journal of Thoracic and Cardiovascular Surgery 2008 136, 688-696DOI: (10.1016/j.jtcvs.2008.05.022) Copyright © 2008 The American Association for Thoracic Surgery Terms and Conditions